[
  {
    "ts": null,
    "headline": "Which Stock Will Dominate the Weight Management Market Through 2030?",
    "summary": "Eli Lilly is a leader in the weight management market, with only a single worthy challenger.  The pharmaceutical giant has a robust pipeline and lineup to lead this space over the next five years.  There are other reasons to invest in Eli Lilly, too, including its efforts to address Alzheimer's disease.",
    "url": "https://finnhub.io/api/news?id=f9171d6848f1d329d28a6765fa49c6ed0b6e1b4016725818752f84ecf6966790",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751107620,
      "headline": "Which Stock Will Dominate the Weight Management Market Through 2030?",
      "id": 135623859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is a leader in the weight management market, with only a single worthy challenger.  The pharmaceutical giant has a robust pipeline and lineup to lead this space over the next five years.  There are other reasons to invest in Eli Lilly, too, including its efforts to address Alzheimer's disease.",
      "url": "https://finnhub.io/api/news?id=f9171d6848f1d329d28a6765fa49c6ed0b6e1b4016725818752f84ecf6966790"
    }
  },
  {
    "ts": null,
    "headline": "Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist’s move followed Eli Lilly’s presentation at the American Diabetes Association (ADA) 85th Annual […]",
    "url": "https://finnhub.io/api/news?id=9cd9f9f315e47ffd6de69ae1a5f26cfdc41c6806b5f5b38ec02aa5cff0fadab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751103675,
      "headline": "Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data",
      "id": 135610869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock. The firm also maintained the price target of $1,038.00. Truist’s move followed Eli Lilly’s presentation at the American Diabetes Association (ADA) 85th Annual […]",
      "url": "https://finnhub.io/api/news?id=9cd9f9f315e47ffd6de69ae1a5f26cfdc41c6806b5f5b38ec02aa5cff0fadab9"
    }
  },
  {
    "ts": null,
    "headline": "Citi Expresses Optimism for Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that “compelling” data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 […]",
    "url": "https://finnhub.io/api/news?id=6796da49f0ac814e2fe6040a44a5fe08734d88a1bb12a1ea5b1f31db4eada211",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751100779,
      "headline": "Citi Expresses Optimism for Eli Lilly and Company (LLY)",
      "id": 135610735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that “compelling” data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 […]",
      "url": "https://finnhub.io/api/news?id=6796da49f0ac814e2fe6040a44a5fe08734d88a1bb12a1ea5b1f31db4eada211"
    }
  }
]